Alteration of serum markers in COVID-19 and implications on mortality

doi:10.1002/ctm2.119

. 2020 Jul;10(3):e119.

doi: 10.1002/ctm2.119. Epub 2020 Jul 21.

Alteration of serum markers in COVID-19 and implications on mortality

Dan Liu¹, Ruyuan Li¹, Ruidi Yu¹, Ya Wang¹, Xinxia Feng², Yuan Yuan¹, Siyuan Wang¹, Shaoqing Zeng¹, Yue Gao¹, Sen Xu¹, Huayi Li¹, Xiaofei Jiao¹, Jianhua Chi¹, Yang Yu¹, Chunyan Song¹, Ning Jin¹, Pengfei Cui¹, Jiahao Liu¹, Xu Zheng¹, Wenjian Gong¹, Xingyu Liu¹, Guangyao Cai¹, Jianming Song³, Susan Yuk-Lin Kwan⁴, Aakash Desai⁵, Chunrui Li⁶, Qinglei Gao¹

Affiliations

¹ National Medical Center for Major Public Health Events, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.
² Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.
³ The Elson S. Floyd College of Medicine, Washington State University, Pullman, Washington, USA.
⁴ Medicine, University of British Columbia, Vancouver, Canada.
⁵ Department of Medicine, University of Connecticut, Farmington, Connecticut, USA.
⁶ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.

PMID: 32696591
PMCID: PMC7404578
DOI: 10.1002/ctm2.119

Alteration of serum markers in COVID-19 and implications on mortality

Dan Liu et al. Clin Transl Med. 2020 Jul.

. 2020 Jul;10(3):e119.

doi: 10.1002/ctm2.119. Epub 2020 Jul 21.

Authors

Affiliations

¹ National Medical Center for Major Public Health Events, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.
² Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.
³ The Elson S. Floyd College of Medicine, Washington State University, Pullman, Washington, USA.
⁴ Medicine, University of British Columbia, Vancouver, Canada.
⁵ Department of Medicine, University of Connecticut, Farmington, Connecticut, USA.
⁶ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.

PMID: 32696591
PMCID: PMC7404578
DOI: 10.1002/ctm2.119

No abstract available

Keywords: COVID-19; cytokine storm; mortality; risk factor.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

**FIGURE 1**
Risk Management during the Clinical Course of COVID‐19. Different strategies of risk management in different periods of COVID‐19. Leukocytosis was defined as white blood cells count greater than 10 × 10⁹/L. Lymphocytopenia was defined as lymphocyte count less than 0.8 × 10⁹/L. Risk factors for male: age ≥ 50 years, with hypertension, D‐dimer > 1 μg/mL, PCT ≥ 0.25 ng/mL, CRP > 10 mg/L, leukocytosis, lymphocytopenia, and IL‐6 ≥ 14 pg/mL. Risk factors for female: IL‐8 ≥ 62 pg/mL, IL‐2R > 710 U/mL, cTnI > 15.6 pg/mL, leukocytosis, lymphocytopenia, and IL‐6 ≥ 14 pg/mL. ^aTime from illness onset

See this image and copyright information in PMC

Cited by

Elevated interleukin-6 and adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates.
Zhang P, Shi L, Xu J, Wang Y, Yang H. Zhang P, et al. Immunogenetics. 2020 Oct;72(8):431-437. doi: 10.1007/s00251-020-01179-1. Epub 2020 Oct 17. Immunogenetics. 2020. PMID: 33067641 Free PMC article.
A retrospective comparison of drugs against COVID-19.
Tan J, Yuan Y, Xu C, Song C, Liu D, Ma D, Gao Q. Tan J, et al. Virus Res. 2021 Mar;294:198262. doi: 10.1016/j.virusres.2020.198262. Epub 2020 Dec 14. Virus Res. 2021. PMID: 33333102 Free PMC article.
Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy.
Lebedeva A, Molodtsov I, Anisimova A, Berestovskaya A, Dukhin O, Elizarova A, Fitzgerald W, Fomina D, Glebova K, Ivanova O, Kalinskaya A, Lebedeva A, Lysenko M, Maryukhnich E, Misyurina E, Protsenko D, Rosin A, Sapozhnikova O, Sokorev D, Shpektor A, Vorobyeva D, Vasilieva E, Margolis L. Lebedeva A, et al. Int J Mol Sci. 2022 Jul 19;23(14):7937. doi: 10.3390/ijms23147937. Int J Mol Sci. 2022. PMID: 35887283 Free PMC article.
Development and validation of an online model to predict critical COVID-19 with immune-inflammatory parameters.
Gao Y, Chen L, Chi J, Zeng S, Feng X, Li H, Liu D, Feng X, Wang S, Wang Y, Yu R, Yuan Y, Xu S, Li C, Zhang W, Li S, Gao Q. Gao Y, et al. J Intensive Care. 2021 Feb 18;9(1):19. doi: 10.1186/s40560-021-00531-1. J Intensive Care. 2021. PMID: 33602326 Free PMC article.

References

1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323:709‐710. - PubMed
1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033‐1034. - PMC - PubMed
1. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID‐19. Arthritis Rheumatology. 2020. - PMC - PubMed
1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID‐19. J Infect. 2020;80(6):607‐613. - PMC - PubMed
1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054‐1062. - PMC - PubMed

Publication types

Actions

Grants and funding

81974405/National Natural Science Foundation of China

LinkOut - more resources

Full Text Sources

[1] Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323:709‐710. - PubMed

[2] Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323:709‐710. - PubMed

[3] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033‐1034. - PMC - PubMed

[4] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033‐1034. - PMC - PubMed

[5] Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID‐19. Arthritis Rheumatology. 2020. - PMC - PubMed

[6] Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID‐19. Arthritis Rheumatology. 2020. - PMC - PubMed

[7] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID‐19. J Infect. 2020;80(6):607‐613. - PMC - PubMed

[8] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID‐19. J Infect. 2020;80(6):607‐613. - PMC - PubMed

[9] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054‐1062. - PMC - PubMed

[10] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054‐1062. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Alteration of serum markers in COVID-19 and implications on mortality

Affiliations

Alteration of serum markers in COVID-19 and implications on mortality

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources